Published in Cell Reports, genetics influence how protective childhood vaccines are, and researchers have found a way of maximising vaccine effectiveness using genome-wide genotyping.
A search in thousands of children in the UK and Netherlands using genome-wide genotyping has revealed genetic variants associated with differing levels of protective antibodies produced after routine childhood immunisations. The findings may inform the development of new vaccine strategies and could lead to personalised vaccination schedules to maximise vaccine effectiveness.
Assessing several million genetic variants
Daniel O’Connor of the University of Oxford, who is co-first author on the paper along with Eileen Png of the Genome Institute of Singapore, explains: “This study is the first to use a genome-wide genotyping approach, assessing several million genetic variants, to investigate the genetic determinants of immune responses to three routine childhood vaccines,”
“While this study is a good start, it also clearly demonstrates that more work is needed to fully describe the complex genetics involved in vaccine responses, and to achieve this aim we will need to study many more individuals.”
Vaccines have revolutionised public health, preventing millions of deaths each year, particularly in childhood. The maintenance of antibody levels in the blood is essential for continued vaccine-induced protection against pathogens.
Yet there is considerable variability in the magnitude and persistence of vaccine-induced immunity. Moreover, antibody levels rapidly wane following immunisation with certain vaccines in early infancy, so boosters are required to sustain protection.
Combatting the burden of infectious disease
“Evoking robust and sustained vaccine-induced immunity from early life is a crucial component of global health initiatives to combat the burden of infectious disease,” O’Connor says.
“The mechanisms underlying the persistence of antibody is of major interest, since effectiveness and acceptability of vaccines would be improved if protection were sustained after infant immunisation without the need for repeated boosting through childhood.”
Vaccine responses and the persistence of immunity are determined by various factors, including age, sex, ethnicity, microbiota, nutritional status, and infectious diseases. Twin studies have also shown vaccine-induced immunity to be highly heritable, and recent studies have started to unpick the genetic components underlying this complex trait.
Details of the study
To explore genetic factors that determine the persistence of immunity, O’Connor and colleagues carried out a genome-wide association study of 3,602 children in the UK and Netherlands.
The researchers focused on three routine childhood vaccines that protect against life-threatening bacterial infections: capsular group C meningococcal (MenC), Haemophilus influenzae type b (Hib), and tetanus toxoid (TT) vaccines.
They analysed approximately 6.7 million genetic variants affecting a single DNA building block, known as single nucleotide polymorphisms (SNPs), associated with vaccine-induced antibody levels in the blood.
The researchers identified two genetic loci associated with the persistence of vaccine-induced immunity following childhood immunisation. The persistence of MenC immunity is associated with SNPs in a genomic region containing a family of signal-regulatory proteins, which are involved in immunological signalling.
Meanwhile, the persistence of TT-specific immunity is associated with SNPs in the human leukocyte antigen (HLA) locus. HLA molecules present peptides to T cells, which in turn induce B cells to produce antibodies.
These variants likely account for only a small portion of the genetic determinants of persistence of vaccine-induced immunity. Moreover, it is unclear whether the findings apply to other ethnic populations besides Caucasians from the UK and Netherlands.
Maximising vaccine effectiveness and paving the way for personalised vaccine
But according to the authors, neonatal screening approaches could soon incorporate genetic risk factors that predict the persistence of immunity, paving the way for personalised vaccine regimens.
“We are now carrying out in-depth investigations into the biology of the genetic variants we described in this study,” O’Connor says. “We also planned further research, in larger cohorts of children and other populations that benefit from vaccination, to further our understanding of how our genetic makeup shapes vaccine responses.”